Sigma-Aldrich, Roche sign distribution agreement for Biochemical Reagents products

NewsGuard 100/100 Score

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, announced today it signed an exclusive global distribution agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The agreement pairs Roche's high-quality Biochemical Reagents product portfolio with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.

Under the agreement, Sigma-Aldrich will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute the Roche Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications.

"Sigma-Aldrich is excited to offer the global scientific community access to Roche's leading portfolio of scientific tools and reagents. The addition of these life science tools supports our strategy to augment our portfolio with products that accelerate customer scientific research programs," said Eric Green, Executive Vice President and President, Sigma-Aldrich Research. "We look forward to working with Roche in this relationship."

"This agreement allows us to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich's expanded eCommerce and distribution networks," said Paul Brown, Head of Roche Molecular Diagnostics. "In addition, this will provide us the flexibility to devote more resources to our primary focus areas."

Transition of the Roche portfolio to Sigma-Aldrich is expected to take place in 2015. In the interim, these products will continue to be available through existing Roche channels.

SOURCE Sigma-Aldrich

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings